Earnings summaries and quarterly performance for Spectral AI.
Executive leadership at Spectral AI.
Board of directors at Spectral AI.
Research analysts who have asked questions during Spectral AI earnings calls.
JV
John Vandermosten
Zacks Small Cap Research
4 questions for MDAI
Also covers: ACHV, BIOR, BLRX +10 more
CB
Carl Byrnes
Northland Capital Markets
3 questions for MDAI
Also covers: ALVO, BLFS, BWAY +6 more
Ryan Zimmerman
BTIG
3 questions for MDAI
Also covers: ALC, GEHC, GKOS +23 more
RS
Ramakanth Swayampakula
H.C. Wainwright & Co., LLC
1 question for MDAI
Also covers: AEMD, CORT, HUMA +1 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for MDAI
Also covers: ABSI, BSEM, CGEN +24 more
VA
Vadim Alexandre Khalil
S.P. Angel
1 question for MDAI
Recent press releases and 8-K filings for MDAI.
Spectral AI Reports Q3 2025 Results, Updates Revenue Guidance, and Provides FDA Submission Progress
MDAI
Earnings
Guidance Update
Product Launch
- Spectral AI reported Q3 2025 research and development revenue of $3.8 million and a net loss of $3.6 million, compared to $8.2 million revenue and a $1.5 million net loss in Q3 2024.
- The company's cash balance was $10.5 million as of September 30, 2025, supplemented by an additional $7.6 million from a registered direct offering in October 2025.
- Full-year 2025 revenue guidance was reduced to $18.5 million from $21.5 million, primarily due to reduced work on the BARDA contract and U.S. government shutdown impacts.
- The FDA de novo application for the DeepView System is progressing, with clearance anticipated in the first half of 2026 and a planned U.S. launch next year.
- The Spectral IP and SIM IP transaction is expected to close in Q1 2026.
Nov 11, 2025, 10:00 PM
Spectral AI Inc. Reports Q2 2025 Results and FDA Submission
MDAI
Earnings
Guidance Update
Product Launch
- Spectral AI, Inc. reported Q2 2025 research and development revenue of $5.1 million and total first-half revenue of $11.8 million, with a cash position of $10.5 million.
- The company completed the submission of its De Novo application to the FDA in June 2025 for its DeepView® System, an AI-powered diagnostic tool for wound care, with initial applications for burns.
- Spectral AI reiterated its 2025 revenue guidance of approximately $21.5 million.
Aug 26, 2025, 12:54 PM
Fintool News
In-depth analysis and coverage of Spectral AI.
Quarterly earnings call transcripts for Spectral AI.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more